Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: September 15th, 2010 - September 15th, 2011

Statement of Need
This CE activity is based on a satellite symposium held in conjunction with the Academy of Managed Care Pharmacy’s 22nd Annual Meeting and Showcase, April 7-10, 2010.


Target Audience
This activity was developed for oncology pharmacists and other healthcare professionals.


Learning Objectives
At the completion of this activity participants should be able to:

  • Describe how a well-planned value-based benefit design can provide oncology patients improved outcomes with few barriers
  • Illustrate how nontraditional outcome measures, such as quality adjusted life-years, can play a role in developing value-based benefit designs for oncology drugs
  • Discuss strategies for overcoming barriers to implementing clinical pathways


Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-027-H01-P.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship( s) they might have with the manufacturer( s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.


Faculty Disclosures
Michael Jacobs, RPh, has nothing to disclose.

Kavita Nair, PhD, is a consultant and researcher for Centocor and a researcher for Amgen, Novartis, and Daiichi Sankyo.

Bruce A. Cutter, MD, MMM, is on the speaker's bureau for Pfizer.

*Content will include non-FDA-approved uses.


The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Value-Based Oncology Benefit Design: Breast Cancer, Multiple Myeloma, and Prostate Cancer
Kavita V. Nair, PhD, Gary M. Owens, MD, Al B. Benson III, MD, FACP
Supplements published on February 20, 2009
Last modified: August 11, 2016